D.E. Shaw & Co
IOVA icon

D.E. Shaw & Co’s Iovance Biotherapeutics IOVA Stock Holding History

D.E. Shaw & Co’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-22,800
Closed -$183K – 4697
2024
Q2 		$183K Sell
22,800
-46,600
-67% -$499K ﹤0.01% 4091
2024
Q1 		$1.03M Buy
+69,400
New +$808K ﹤0.01% 3078
2020
Q3 		– Sell
-20,000
Closed -$549K – 3982
2020
Q2 		$549K Sell
20,000
-20,000
-50% -$658K ﹤0.01% 3302
2020
Q1 		$1.2M Buy
+40,000
New +$1.06M ﹤0.01% 2595

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

D.E. Shaw & Co's IOVA Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Iovance Biotherapeutics (IOVA) stake by 73% in Q2 2026, selling an estimated $22.3M and leaving 2,143,134 shares worth $8.92M. The position accounts for ﹤0.01% of the portfolio, ranked #1921.

D.E. Shaw & Co first reported a position in IOVA in Q2 2015 and has held it in 32 quarters since. The position peaked at $34.9M in Q1 2024. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • D.E. Shaw & Co held 2,143,134 shares of Iovance Biotherapeutics worth $8.92M as of Q2 2026.
  • D.E. Shaw & Co sold 5,873,219 Iovance Biotherapeutics shares in Q2 2026, an estimated $22.3M.
  • Iovance Biotherapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #1921 holding.
  • D.E. Shaw & Co first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 32 quarters since.
  • D.E. Shaw & Co's Iovance Biotherapeutics position peaked at $34.9M in Q1 2024.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.